Blue Cross Blue Shield · Riociguat · US health-plan appeal rights

Riociguat denied as non-formulary by Blue Cross Blue Shield?

Q: How long do I have to appeal a Blue Cross Blue Shield Riociguat denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

Non-formulary doesn't mean uncoverable. Most plans have a formulary-exception process: the appeal needs to show the formulary alternatives are inappropriate for your specific clinical situation.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-09

Policy data current as of 2026-04-26

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Blue Cross Blue Shield typically requires

PAH: WHO Group 1, RHC-confirmed, FC II–III, age ≥18. CTEPH: WHO Group 4, V/Q-confirmed, surgically inoperable or persistent/recurrent post-pulmonary endarterectomy (PEA), evaluated at CTEPH center. NEVER co-administer with PDE5i (contraindication). Pregnancy REMS.

Source policy: BCBS Adempas (Riociguat) for PAH and Inoperable / Persistent CTEPH (Policy #5.01.605)

What works in the appeal

Adempas is the ONLY FDA-approved therapy (Oct 8, 2013) for inoperable or persistent/recurrent post-PEA CTEPH — based on CHEST-1 Ghofrani NEJM 2013;369(4):319-329 (PVR −246 dyn·s·cm⁻⁵, 6MWD +46 m). For PAH: PATENT-1 Ghofrani NEJM 2013;369(4):330-340 (6MWD +36 m). Riociguat is an sGC stimulator NOT a PDE5i — distinct upstream NO pathway target; PDE5i co-administration contraindicated due to hypotension. For PDE5i non-responders RESPITE Hoeper ERJ 2017 supports switch to riociguat. Document inoperability assessment at CTEPH center before denial of inoperable CTEPH indication.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Blue Cross Blue Shield appeals

Other denial reasons for Blue Cross Blue Shield Riociguat

denied as not medically necessary denied for failing step therapy denied for missing prior authorization denied as experimental or investigational denied as not FDA-approved for this use

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-09. Editorial standards: denialhelp.com/authors.